Literature DB >> 18606088

Biologic agents in the management of inflammatory eye diseases.

Kira Michalova1, Lyndell Lim.   

Abstract

Biologics are a new class of drugs that comprise recombinant cytokines and monoclonal antibodies directed against selected cell-surface markers. They include the tumor necrosis factor-alpha inhibitors infliximab, etanercept, and adalimumab; the antilymphocyte drugs rituximab and alemtuzumab; the interleukin-2 receptor blocker daclizumab; and recombinant interferon-alpha. This article reviews the rationale and current evidence for their use in uveitis, scleritis, and orbital inflammation.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18606088     DOI： 10.1007/s11882-008-0054-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN： 1529-7322            Impact factor:   4.806


  60 in total

1.  Adalimumab: a new modality for Behçet's disease?

Authors:  J A M van Laar; T Missotten; P L A van Daele; A Jamnitski; G S Baarsma; P M van Hagen
Journal:  Ann Rheum Dis       Date:  2006-11-23       Impact factor: 19.103

2.  Successful treatment of Wegener's granulomatosis associated scleritis with rituximab.

Authors:  C M G Cheung; P I Murray; C O S Savage
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

Authors:  Pierre Quartier; Pierre Taupin; Franck Bourdeaut; Irène Lemelle; Pascal Pillet; Michel Bost; Jean Sibilia; Isabelle Koné-Paut; Sylvie Gandon-Laloum; Marc LeBideau; Brigitte Bader-Meunier; Richard Mouy; Marianne Debré; Paul Landais; Anne-Marie Prieur
Journal:  Arthritis Rheum       Date:  2003-04

5.  Anti-TNF-alpha therapy for sight threatening uveitis.

Authors:  E W Lindstedt; G S Baarsma; R W A M Kuijpers; P M van Hagen
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

6.  Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study.

Authors:  Christoph M E Deuter; Ina Koetter; Ilhan Guenaydin; Nicole Stuebiger; Manfred Zierhut
Journal:  Retina       Date:  2006-09       Impact factor: 4.256

7.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

Authors:  R B Nussenblatt; E Fortin; R Schiffman; L Rizzo; J Smith; P Van Veldhuisen; P Sran; A Yaffe; C K Goldman; T A Waldmann; S M Whitcup
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

8.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Authors:  Robert P Baughman; Marjolein Drent; Mani Kavuru; Marc A Judson; Ulrich Costabel; Roland du Bois; Carlo Albera; Martin Brutsche; Gerald Davis; James F Donohue; Joachim Müller-Quernheim; Rozsa Schlenker-Herceg; Susan Flavin; Kim Hung Lo; Barry Oemar; Elliot S Barnathan
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

9.  Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.

Authors:  Robert P Baughman; Elyse E Lower; Deborah A Bradley; Lawrence A Raymond; Adam Kaufman
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

10.  Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up.

Authors:  Stacy P Ardoin; Deborah Kredich; Egla Rabinovich; Laura E Schanberg; Glenn J Jaffe
Journal:  Am J Ophthalmol       Date:  2007-10-22       Impact factor: 5.258
View more
  8 in total

1.  Treating refractory scleritis with infliximab.

Authors:  Seong Joon Ahn; Joo Youn Oh; Mee Kum Kim; Won Ryang Wee
Journal:  Jpn J Ophthalmol       Date:  2009-05-31       Impact factor: 2.447

Review 2.  Therapeutic Potential of Exosomes Derived from Adipose Tissue-Sourced Mesenchymal Stem Cells in the Treatment of Neural and Retinal Diseases.

Authors:  Carl Randall Harrell; Vladislav Volarevic; Valentin Djonov; Ana Volarevic
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

Review 3.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

4.  Adalimumab for Ocular Inflammation.

Authors:  Khayyam Durrani; John H Kempen; Gui-Shuang Ying; R Oktay Kacmaz; Pichaporn Artornsombudh; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; C Stephen Foster
Journal:  Ocul Immunol Inflamm       Date:  2016-03-22       Impact factor: 3.070

5.  Anti-angiogenic effect of a humanized antibody blocking the Wnt/β-catenin signaling pathway.

Authors:  Fangfang Qiu; Younghwa Shin; Danyang Chen; Rui Cheng; Qian Chen; Kelu Zhou; James W Larrick; Andrew R Mendelson; Jian-Xing Ma
Journal:  Microvasc Res       Date:  2018-04-07       Impact factor: 3.514

6.  Anti-angiogenic and anti-inflammatory effects of SERPINA3K on corneal injury.

Authors:  Xiaochen Liu; Zhirong Lin; Tong Zhou; Ronrong Zong; Hui He; Zhen Liu; Jian-xing Ma; Zuguo Liu; Yueping Zhou
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

Review 7.  The Role of Limbal Epithelial Stem Cells in Regulating Corneal (Lymph)angiogenic Privilege and the Micromilieu of the Limbal Niche following UV Exposure.

Authors:  M Notara; A Lentzsch; M Coroneo; C Cursiefen
Journal:  Stem Cells Int       Date:  2018-05-08       Impact factor: 5.443

8.  UV light-blocking contact lenses protect against short-term UVB-induced limbal stem cell niche damage and inflammation.

Authors:  M Notara; S Behboudifard; M A Kluth; C Maßlo; C Ganss; M H Frank; B Schumacher; C Cursiefen
Journal:  Sci Rep       Date:  2018-08-22       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.